NCT06225427View on ClinicalTrials.gov

Gilteritinib for the Treatment of ALK NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Interventions
PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography

Undergo echocardiography

DRUG

Gilteritinib

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

20007

NOT_YET_RECRUITING

Georgetown University, Washington D.C.

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

90048

NOT_YET_RECRUITING

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER